Mick R - Search Results

1

Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2^pos DCIS Independent of Route: Results of Randomized Selection Design Trial.

Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, Fox KR, DeMichele A, Zhang PJ, Weinstein SP, Roses RE, Czerniecki BJ. Lowenfeld L, et al. Among authors: mick r. Clin Cancer Res. 2017 Jun 15;23(12):2961-2971. doi: 10.1158/1078-0432.CCR-16-1924. Epub 2016 Dec 13. Clin Cancer Res. 2017. PMID: 27965306 Clinical Trial.

2

Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ. Czerniecki BJ, et al. Among authors: mick r. Cancer Res. 2007 Feb 15;67(4):1842-52. doi: 10.1158/0008-5472.CAN-06-4038. Epub 2007 Feb 9. Cancer Res. 2007. PMID: 17293384 Clinical Trial.

3

Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance.

Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR, DeMichele A, Schuchter LM, Leibowitz MS, Wexler MH, Vance BA, Beatty GL, Veloso E, Feldman MD, Vonderheide RH. Domchek SM, et al. Among authors: mick r. Cancer Res. 2007 Nov 1;67(21):10546-55. doi: 10.1158/0008-5472.CAN-07-2765. Cancer Res. 2007. PMID: 17974999

4

HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.

Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ. Sharma A, et al. Among authors: mick r. Cancer. 2012 Sep 1;118(17):4354-62. doi: 10.1002/cncr.26734. Epub 2012 Jan 17. Cancer. 2012. PMID: 22252842 Free PMC article. Clinical Trial.

5

Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS.

Fracol M, Xu S, Mick R, Fitzpatrick E, Nisenbaum H, Roses R, Fisher C, Tchou J, Fox K, Zhang P, Czerniecki BJ. Fracol M, et al. Among authors: mick r. Ann Surg Oncol. 2013 Oct;20(10):3233-9. doi: 10.1245/s10434-013-3119-y. Epub 2013 Jul 13. Ann Surg Oncol. 2013. PMID: 23851609

6

Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER^pos/HER2^pos early breast cancer.

Lowenfeld L, Zaheer S, Oechsle C, Fracol M, Datta J, Xu S, Fitzpatrick E, Roses RE, Fisher CS, McDonald ES, Zhang PJ, DeMichele A, Mick R, Koski GK, Czerniecki BJ. Lowenfeld L, et al. Among authors: mick r. Oncoimmunology. 2016 Jul 1;6(9):e1207032. doi: 10.1080/2162402X.2016.1207032. eCollection 2017. Oncoimmunology. 2016. PMID: 28932627 Free PMC article.

7

Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.

Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ. Bedrosian I, et al. Among authors: mick r. J Clin Oncol. 2003 Oct 15;21(20):3826-35. doi: 10.1200/JCO.2003.04.042. J Clin Oncol. 2003. PMID: 14551301 Clinical Trial.

8

Anti-HER2 CD4⁺ T-Helper Type 1 Immune Response is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer.

De La Cruz LM, McDonald ES, Mick R, Datta J, Nocera NF, Xu S, Fisher CS, Czerniecki BJ. De La Cruz LM, et al. Among authors: mick r. Ann Surg Oncol. 2017 Apr;24(4):1057-1063. doi: 10.1245/s10434-016-5651-z. Epub 2016 Nov 8. Ann Surg Oncol. 2017. PMID: 27826664

9

Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma.

Downes KJ, Glatt BS, Kanchwala SK, Mick R, Fraker DL, Fox KR, Solin LJ, Bucky LP, Czerniecki BJ. Downes KJ, et al. Among authors: mick r. Cancer. 2005 Mar 1;103(5):906-13. doi: 10.1002/cncr.20851. Cancer. 2005. PMID: 15651068 Free article.

10

The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.

Harada S, Mick R, Roses RE, Graves H, Niu H, Sharma A, Schueller JE, Nisenbaum H, Czerniecki BJ, Zhang PJ. Harada S, et al. Among authors: mick r. J Surg Oncol. 2011 Oct;104(5):458-65. doi: 10.1002/jso.21973. Epub 2011 May 9. J Surg Oncol. 2011. PMID: 21557226 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

260 results

Search Page